Khalid S Mohammad
Overview
Explore the profile of Khalid S Mohammad including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
2829
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dawalibi A, Alosaimi A, Mohammad K
Int J Mol Sci
. 2024 Aug;
25(15).
PMID: 39125732
Bone metastases, a common and debilitating consequence of advanced cancers, involve a complex interplay between malignant cells and the bone microenvironment. Central to this interaction are interleukins (ILs), a group...
2.
Arakil N, Akhund S, Elaasser B, Mohammad K
Biomedicines
. 2024 May;
12(5).
PMID: 38791037
The phenomenon of bone metastases presents a significant challenge within the context of advanced cancer treatments, particularly pertaining to breast, prostate, and lung cancers. These metastatic occurrences stem from the...
3.
Elaasser B, Arakil N, Mohammad K
Int J Mol Sci
. 2024 Mar;
25(5).
PMID: 38474093
The treatment of patients with advanced cancer poses clinical problems due to the complications that arise as the disease progresses. Bone metastases are a common problem that cancer patients may...
4.
Liu Y, Reiken S, Dridi H, Yuan Q, Mohammad K, Trivedi T, et al.
Sci Transl Med
. 2023 Sep;
15(715):eadf8977.
PMID: 37756377
Chemotherapy-induced cognitive dysfunction (chemobrain) is an important adverse sequela of chemotherapy. Chemobrain has been identified by the National Cancer Institute as a poorly understood problem for which current management or...
5.
Trivedi T, Manaa M, John S, Reiken S, Murthy S, Pagnotti G, et al.
bioRxiv
. 2023 Jun;
PMID: 37333318
Summary: Zoledronic acid (ZA) prevents muscle weakness in mice with bone metastases; however, its role in muscle weakness in non-tumor-associated metabolic bone diseases and as an effective treatment modality for...
6.
Pagnotti G, Trivedi T, Wright L, John S, Murthy S, Pattyn R, et al.
bioRxiv
. 2023 Mar;
PMID: 36993656
Translational Relevance: Postmenopausal patients with estrogen receptor-positive breast cancer treated with aromatase inhibitors to reduce tumor progression experience deleterious effects to bone and muscle subsequently develop muscle weakness, bone fragility,...
7.
Pagnotti G, Trivedi T, Mohammad K
Cells
. 2022 Apr;
11(8).
PMID: 35455987
Metastatic bone disease is a common and devastating complication to cancer, confounding treatments and recovery efforts and presenting a significant barrier to de-escalating the adverse outcomes associated with disease progression....
8.
Liu L, Li H, Patterson A, Plett P, Sampson C, Mohammad K, et al.
Stem Cell Rev Rep
. 2022 Mar;
18(4):1478-1494.
PMID: 35318613
Exposure to potentially lethal high-dose ionizing radiation results in bone marrow suppression, known as the hematopoietic acute radiation syndrome (H-ARS), which can lead to pancytopenia and possible death from hemorrhage...
9.
Trivedi T, Pagnotti G, Guise T, Mohammad K
Biomolecules
. 2021 Nov;
11(11).
PMID: 34827641
Complications associated with advanced cancer are a major clinical challenge and, if associated with bone metastases, worsen the prognosis and compromise the survival of the patients. Breast and prostate cancer...
10.
Wang R, Kumar B, Bhat-Nakshatri P, Prasad M, Jacobsen M, Ovalle G, et al.
JCSM Rapid Commun
. 2021 Apr;
4(1):24-39.
PMID: 33842876
Background: Loss of skeletal muscle volume and resulting in functional limitations are poor prognostic markers in breast cancer patients. Several molecular defects in skeletal muscle including reduced MyoD levels and...